表紙
市場調査レポート

Tris Pharma, Inc.の製品パイプライン分析

Tris Pharma, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 317363
出版日 ページ情報 英文 20 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
Tris Pharma, Inc.の製品パイプライン分析 Tris Pharma, Inc. - Product Pipeline Review - 2015
出版日: 2015年11月18日 ページ情報: 英文 20 Pages
概要

Tris Pharma, Inc.は米国に本社をおく製薬企業で、咳、風、疼痛管理、神経性疾患の治療に使われるOTC薬、RXブランド薬、特殊なジェネリック製品の研究開発および製造を行っています。

当レポートでは、Tris Pharma, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Tris Pharma, Inc.の基本情報

  • Tris Pharma, Inc.の概要
  • 主要情報
  • 企業情報

Tris Pharma, Inc.:R&Dの概要

  • 主な治療範囲

Tris Pharma, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Tris Pharma, Inc.:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 新薬登録前段階の製品/併用療法モダリティ
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床試験段階の製品/併用療法モダリティ
  • 開発段階が不明のパイプライン製品
    • 開発段階が不明の製品/併用療法モダリティ

Tris Pharma, Inc.:薬剤プロファイル

  • CCP-01
  • TRI-102
  • CCP-07
  • CCP-08
  • CCP-05
  • CCP-06
  • TRI-091
  • TRI-096

Tris Pharma, Inc.:パイプライン分析

  • 投与経路別
  • 分子タイプ別

Tris Pharma, Inc.:最新のパイプライン情報

Tris Pharma, Inc.:開発休止中のプロジェクト

Tris Pharma, Inc.:企業理念

Tris Pharma, Inc.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07752CDB

Summary

Global Markets Direct's, 'Tris Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Tris Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tris Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Tris Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Tris Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Tris Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Tris Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Tris Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Tris Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Tris Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tris Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Tris Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Tris Pharma, Inc. Snapshot
    • Tris Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • Tris Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Tris Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Tris Pharma, Inc. - Pipeline Products Glance
    • Tris Pharma, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Tris Pharma, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Tris Pharma, Inc. - Drug Profiles
    • TRI-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRI-091
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRI-096
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tris Pharma, Inc. - Pipeline Analysis
    • Tris Pharma, Inc. - Pipeline Products by Route of Administration
  • Tris Pharma, Inc. - Recent Pipeline Updates
  • Tris Pharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Tris Pharma, Inc., Key Information
  • Tris Pharma, Inc., Key Facts
  • Tris Pharma, Inc. - Pipeline by Indication, 2015
  • Tris Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Tris Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Tris Pharma, Inc. - Partnered Products in Pipeline, 2015
  • Tris Pharma, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Tris Pharma, Inc. - Phase III, 2015
  • Tris Pharma, Inc. - Unknown, 2015
  • Tris Pharma, Inc. - Pipeline by Route of Administration, 2015
  • Tris Pharma, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Tris Pharma, Inc. - Pipeline by Top 10 Indication, 2015
  • Tris Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Tris Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Tris Pharma, Inc. - Partnered Products in Pipeline, 2015
  • Tris Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2015
Back to Top